Quantum News
Sign InSign Up
Back to News
research

Oxford Biomedica plc (OXBDF) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Oxford Biomedica’s CEO Frank Mathias highlighted 2025 as a year of strategic growth, reinforcing its position as a leading global cell and gene therapy CDMO through expanded capabilities and partnerships. Commercial momentum surged in 2025, driven by rising demand for gene therapies, with Chief Business Officer Sebastien Ribault citing robust market fundamentals and a strengthened pipeline of client contracts. CFO Lucinda Crabtree presented financial results showing revenue growth, though specifics were not detailed in the transcript, emphasizing operational efficiency and reinvestment in scalable manufacturing. The company underscored advancements in lentiviral vector technology, a critical component for gene therapies, positioning Oxford Biomedica as a key enabler for next-generation treatments. Analysts from RBC, JPMorgan, and Deutsche Bank probed growth strategies, manufacturing capacity, and R&D priorities, signaling strong investor interest in the sector’s long-term potential.
AI Audio Summary
0:00 / 0:00
Click to play
8eaedf23-5eba-49d5-9b8a-62223a528def.jpeg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159.12K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Oxford Biomedica plc (OXBDF) Q4 2025 Earnings Call March 26, 2026 9:00 AM EDT Company Participants Frank Mathias - CEO & DirectorSebastien Ribault - Chief Business OfficerLucinda Crabtree - CFO & Director Conference Call Participants Charles Weston - RBC Capital Markets, Research DivisionZain Ebrahim - JPMorgan Chase & Co, Research DivisionKane Slutzkin - Deutsche Bank AG, Research DivisionJulie Simmonds - Panmure Liberum Limited, Research DivisionMiles Dixon - Peel Hunt LLP, Research Division Presentation Operator Hello, and welcome to OXB 2025 Preliminary Results. We are joined today by Dr. Frank Mathias, Chief Executive Officer; Dr. Lucinda Crabtree, Chief Financial Officer; and Dr. Sebastien Ribault, Chief Business Officer. [Operator Instructions] I would now like to hand the call over to Dr. Frank Mathias. Please go ahead. Frank MathiasCEO & Director Thank you so much for the introduction. Good morning to those in the U.S., and good afternoon to everyone else, and thank you for joining our OXB preliminary results briefing for the full year of 2025. Presenting alongside I just mentioned with me today is our Chief Financial Officer, Dr. Lucinda Crabtree; as well as our Chief Business Officer, Dr. Sebastien. Next slide, please. Before we begin -- sorry, one back -- sorry. Before we begin, I will quickly run through today's meeting agenda as seen now on the screen. We'll begin with the business update, providing an overview of OXB's key achievements over the period and highlighting the steps we have taken this year to further strengthen our position as a leading global cell and gene therapy CDMO. I will then hand over to Sebastien, who will provide an update on the strong commercial momentum we are seeing across the business and the positive fundamentals of the cell and gene therapy market. Lucy will then take us through the group financial performance in 2025 before handing back to me for closing remarks

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.